| Literature DB >> 36091445 |
Wenqian Li1,2, Can Huang1,2, Jingyu Chen1,2.
Abstract
Clustered regularly interspaced short palindromic repeats (CRISPR) and its associated enzymes (Cas) is a simple and convenient genome editing tool that has been used in various cell factories and emerging synthetic biology in the recent past. However, several problems, including off-target effects, cytotoxicity, and low efficiency of multi-gene editing, are associated with the CRISPR/Cas system, which have limited its application in new species. In this review, we briefly describe the mechanisms of CRISPR/Cas engineering and propose strategies to optimize the system based on its defects, including, but not limited to, enhancing targeted specificity, reducing toxicity related to Cas protein, and improving multi-point editing efficiency. In addition, some examples of improvements in synthetic biology are also highlighted. Finally, future perspectives of system optimization are discussed, providing a reference for developing safe genome-editing tools for new species.Entities:
Keywords: CRISPR/Cas; gene-editing efficiency; off-target effects; synthetic biology; toxicity
Year: 2022 PMID: 36091445 PMCID: PMC9452635 DOI: 10.3389/fbioe.2022.890155
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Improved CRISPR/Cas system involving Cas protein, gRNA and donor DNA.
| Strategies | Descriptions | Characteristics | Ref |
|---|---|---|---|
| Cas proteins optimization strategy | |||
| xCas9 or Cas9-NG | Engineered versions of | Improve target specificity and expand target range |
|
| Cas9n | Inactivating the HNH or RuvC nuclease domain of Cas9 | Edit specific sites |
|
| dCas9 | Inactivating both HNH and RuvC nuclease domain of Cas9 | Base editing without generation of DSBs |
|
| spCas9-HF1 | Mutation of the key amino acid residues of SpCas9 responsible for contact with the target sequence | Variants that reduced nonspecific DNA interactions |
|
| espCas9 |
| Requirement of a high specificity |
|
| Cpf1 | Type Ⅱ-Ⅴ CRISPR system | Cpf1 recognizes T-rich PAM, and is degraded by the endogenous protease system after editing |
|
| HypaCas9 | Balance nuclease activation and target recognition | Higher genome-wide fidelity |
|
| Sniper-Cas | An | Higher specificity |
|
| sgRNA optimization strategy | |||
| Individual promoters/terminators | Each sgRNA has independent promoter and terminator control | High efficiency and wide application, but unstable because of large structure and repeat sequences |
|
| Type Ⅱ CRISPR crRNA array | Multiple sgRNA expression using crRNA array via one promoter and one terminator | The structure is simple, but the complementary pairing of pre-crRNA and trans-activating crRNA and the intracellular RNase III nuclease need to be considered |
|
| ABEs or CBEs | Transcriptome-wide gRNA-independent editing of RNA bases | Low DNA off-target and indels formation activity |
|
| tRNA processing | Multiple sgRNA are controlled by one promoter and one terminator based on endogenous ribozymes, tRNA processing, and exogenous Csy4 protein | No need to introduce heterologous Cas protein, and showed more stable in multi-site editing |
|
| Prime editing (PE) | No DSB or donor DNA is required | 89% of known genetic variations associated with human disease can be corrected |
|
| DONOR DNA optimization strategy | |||
| ssDNA | Single-stranded DNA | Simple to prepare, but limited in length |
|
| dsDNA | Double-stranded DNA | More stable than ssDNA |
|
| plasmids | Donor DNA templates are provided as plasmids | The plasmid transformation efficiency is high and stable, but the operation is complicated, and the number of plasmids available in some engineered strains is limited |
|
FIGURE 2Strategies for reducing CRISPR/Cas9 system cytotoxicity. (A) Replacing Cas9 with other less toxic Cas proteins, such as dCas9 and CpfI; (B) Using the intracellular endogenous CRISPR/Cas immune system to express crRNA and realized target sites-editing; (C) Introducing exogenous NHEJ recombination system to reduce DSB induced cytotoxicity; (D) Emerging CRISPR gene editing based on transposons.
FIGURE 1Limitations and advantages of CRISPR/Cas9.
FIGURE 3Mechanism and optimization strategy of CRISPR/Cas9 gene-editing system. Cas9 protein cleaves double-stranded DNA under the guidance of sgRNA to obtain DSB. Precise editing by the introduction of donor DNA in cells with HDR machinery, or formation of indels in cells with NHEJ repair machinery. A- C describes general optimization strategies. (A) Cas9 nickase; (B) Dead Cas9; (C) The other Cas proteins. (D) Independent expression of sgRNA; (E) Simultaneous expression of multiple sgRNAs; (F) tRNA process; (G) Donor DNA is provided as ssDNA; (H) Donor DNA is provided as dsDNA; (I) Donor DNA is provided as a plasmid. Recent applications of CRISPR/Cas engineering.
Recent applications of CRISPR/Cas engineering in prokaryotes.
| Strains | Stratges | Applications | Efficiency | Ref |
|---|---|---|---|---|
|
| CRISPRi and 27 arrays containing sgRNAs with different repression capacities targeting the | N-acetylglucosamine | The production of N-acetylglucosamine increased 84.1% and a 3-L fed-batch bioreactor reached 103.1 ± 2.11 g/L and 1.17 ± 0.024 g/L/h |
|
|
| CRISPR Cascade system | Alanine | The overall yield in this process was 0.74 g ala- nine/g of glucose, with the yield in the production phase reaching 0.81 g alanine/g of glucose |
|
|
| A multi-gene CRISPRi/a control program | Ethanol | The production quadrupled |
|
|
| CRISPR/Cas9-facilitated multiplex pathway optimization technique (regulating the expression of multiple genes) | Xylose | The utilization rate increased by 3 times |
|
|
| Multiplex CRISPRi | Malic acid | A 2.3-fold increase |
|
|
| Multiplex CRISPRi | Squalene | 3.4 times higher than that of the parental strains |
|
|
| Multiplex CRISPRi | L-pyrrolysine | Production improved by 39% compared with wild-type |
|
|
| Multiplex CRISPRi | Octadecanol | Increased octadecanol productivity threefold |
|
|
| CRISPRi with trp operon | 1, 3-propylene glycol and 3-hydroxypropionic acid (3-HP) | Produced 58.9 g/L 3- HP in a 5 L bioreactor |
|